We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+10.81%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.37B
AUM Growth
+$626M
Cap. Flow
+$276M
Cap. Flow %
3.75%
Top 10 Hldgs %
69.13%
Holding
47
New
6
Increased
11
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$126M
2
KRYS icon
Krystal Biotech
KRYS
+$82.8M
3
ROIV icon
Roivant Sciences
ROIV
+$51.9M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$46.4M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$44.1M

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$60.5M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$41M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.9M
4
NUVL
Nuvalent
NUVL
+$10.9M
5
ARGX icon
argenx
ARGX
+$9.44M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$2.46B
$34.6M 0.47%
750,000
– –
MRNS
27
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$34.2M 0.46%
3,150,000
– –
KURA icon
28
Kura Oncology
KURA
$817M
$32.9M 0.45%
3,105,000
– –
GLUE icon
29
Monte Rosa Therapeutics
GLUE
$1.32B
$31.1M 0.42%
4,535,000
+210,000
+5% +$1.36M
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$27.8M 0.38%
2,510,000
– –
DSGN icon
31
Design Therapeutics
DSGN
$849M
$22.1M 0.3%
3,500,000
– –
MRSN
32
DELISTED
Mersana Therapeutics
MRSN
$21M 0.28%
255,000
-47,000
-16% -$6.88M
WHWK
33
Whitehawk Therapeutics
WHWK
$201M
$19.5M 0.26%
2,849,402
– –
PMVP icon
34
PMV Pharmaceuticals
PMVP
$62.4M
$19.2M 0.26%
3,060,000
– –
VRCA icon
35
Verrica Pharmaceuticals
VRCA
$94.7M
$17M 0.23%
295,406
+30,406
+11% +$1.85M
ARWR icon
36
Arrowhead Research
ARWR
$12.2B
$12.7M 0.17%
+357,403
New +$12.3M
MCRB icon
37
Seres Therapeutics
MCRB
$48.4M
$12M 0.16%
125,000
+60,250
+93% +$6.56M
IMA
38
ImageneBio Inc
IMA
$65.4M
$10.8M 0.15%
+136,667
New +$9.8M
FENC icon
39
Fennec Pharmaceuticals
FENC
$365M
$10.6M 0.14%
1,200,000
– –
TNGX icon
40
Tango Therapeutics
TNGX
$4.69B
$5.44M 0.07%
1,640,000
– –
IOBT
41
DELISTED
IO Biotech
IOBT
$4.03M 0.05%
2,055,883
– –
TRML
42
DELISTED
Tourmaline Bio
TRML
$1.52M 0.02%
+50,000
New +$1.28M
SYRE icon
43
Spyre Therapeutics
SYRE
$9.06B
$129K ﹤0.01%
+11,458
New +$54.3K
AMLX icon
44
Amylyx Pharmaceuticals
AMLX
$2.43B
– –
-473,100
Closed -$13.9M
SRPT icon
45
CALL
Sarepta Therapeutics
SRPT
$1.68B
– –
-250,000
Closed -$3.67M
XBI icon
46
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.99B
– –
-1,500,000
Closed -$180K
ISEE
47
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-875,000
Closed -$1.84M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Avoro Capital Advisors held 47 positions worth $7.37B, up 9.3% from $6.75B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors deployed $276M of net new capital in Q2 2023, opening 6 new positions and adding to 11 existing holdings. Its largest new stake was Roivant Sciences: 5,806,162 shares worth $58.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was DICE Therapeutics, Inc. Common Stock, an estimated $60.5M trimmed.

  • Avoro Capital Advisors's largest Q2 2023 buy was Roivant Sciences: 5,806,162 shares worth $58.5M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q2 2023, an estimated $126M increase.
  • Avoro Capital Advisors's biggest Q2 2023 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $60.5M.
  • Avoro Capital Advisors fully exited Amylyx Pharmaceuticals in Q2 2023, selling an estimated $13.9M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $7.37B portfolio in Q2 2023.
  • Avoro Capital Advisors opened 6 new positions and closed 4 in Q2 2023.
  • Avoro Capital Advisors's portfolio value rose 9.3% quarter-over-quarter to $7.37B.

Based on Avoro Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.